U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. For Consumers
  3. Women's Health
  4. Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender - 09/27/2018
  1. Women's Health

Symposium | Virtual

Event Title
Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
September 27 - 28, 2018


Date:
September 27 - 28, 2018
Time:
8:00 AM - 4:00 PM ET
Organized By:

Sex differences may influence susceptibility to substance abuse, which could have implications for optimal prevention and treatment. Gender influences also impact public health from an environmental perspective. To identify and treat women most at risk, researchers, educators, and clinicians must be able to recognize and consider both sex and gender differences.

The U.S. Food and Drug Administration’s Office of Women’s Health, in collaboration with the Center for Drug Evaluation and Research and the Center for Tobacco Products, will be hosting a 2-day public meeting, “Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender,” to address this important issue. The conference will include presentations by experts in the field of opioid and tobacco research, professional education, and clinical care on the biological (sex) and sociological (gender) influences on use, misuse, and recovery.

Webcast Recording Day 1- Sept 27 2018

Webcast Recording Day 2- Sept 28 2018

Keynote Speakers

Day 1

Commissioner Scott Gottlieb, MD

Scott Gottlieb, M.D.
Commissioner of Food and Drugs

Day 2

RADM Sylvia Trent-Adams, PhD, RN, FAAN

RADM Sylvia Trent-Adams, Ph.D, R.N., F.A.A.N.
Deputy U.S. Surgeon General

 

When: Thursday, September 27, 2018, and Friday, September 28, 2018, from 8:30 a.m. - 4:00 p.m.

Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender

Executive Steering Committee (ESC)
Committee Member  Title
Ami Bahde, MPH Program Analyst, FDA CTP
Terri Cornelison, MD, PhD, FACOG Assistant Director for the Health of Women, FDA CDRH
Carolyn Dresler, MD, MPA  Associate Director For Medical and Health Sciences, FDA CTP
Marjorie Jenkins, MD, MEdHP, FACP Director of Medical Initiatives and Scientific Engagement, FDA OWH
Tamra Meyer, PhD, MPH  Lead Epidemiologist, FDA CDER OSE 
Pamela Scott, PhD  Deputy Director, Office of Women's Health; Director of Research and Development, FDA OWH 
Jessica Tytel, MPH  Senior Advisor, HHS OWH 
Rita Valentino, PhD  Director, Division of Neuroscience and Behavior, NIH NIDA 
Cora Lee Wetherington, PhD  Women & Sex/Gender Differences Research Coordinator, NIH NIDA
Celia Winchell, MD  Medical Officer Team Leader (addiction, drugs), FDA CDER DAAAP 

 

Scientific Planning Committee (SPC)
Committee Member  Title
Lori Bastian, MD, MPH Professor of Internal Medicine (General Medicine);
Section Chief of General Internal Medicine, VA Connecticut Healthcare System;
Director, Pain Research, Informatics, Multimorbidities, and Education (PRIME) Center
Jill Becker, PhD Research Professor, Department of Psychiatry, Molecular and
Behavioral Neuroscience Institute, University of Michigan
Michele Bloch, MD, PhD Chief, Tobacco Control Research Branch, Behavioral Research Program, NIH NCI
Kathleen Brady, MD, PhD Distinguished University Professor, Associate Provost, Clinical and Translational Science;
Director, South Carolina Clinical and Translational Research Institute (SCTR),
Medical University of South Carolina
Terri Cornelison, MD, PhD, FACOG Assistant Director for the Health of Women, FDA CDRH
Carolyn Dresler, MD, MPA  Associate Director for Medical and Health Sciences, FDA CTP
Phyllis E. Greenberger, MSW Senior VP of Science and Health Policy, Healthy Women
Gioia Guerrieri, DO Medical Officer, CDER DAAAP
Amber Jessup, PhD Senior Economist, HHS ASPE
Marjorie Jenkins, MD, MEdHP, FACP Director of Medical Initiatives and Scientific Engagement, FDA OWH
Hendrée Jones, PhD Professor, Department of Obstetrics and Gynecology;
Executive Director of UNC Horizons, University of North Carolina Chapel Hill School of Medicine
Karin Mack, PhD Science Officer, CDC 
Sherry McKee, PhD Professor of Psychiatry; Director, Yale Behavioral Pharmacology Laboratory;
Clinical Director, Forensic Drug Diversion Clinic;
Director, Yale-SCOR to Develop Gender-Sensitive Therapeutics for Addiction
Yale University School of Medicine 
Chad D. Morris, PhD Associate Professor, Department of Psychiatry,
Director of the Behavioral Health and Wellness Program,
Co-Director of the Wellness Leadership Institute, University of Colorado 
Judith (Jodi) Prochaska, PhD, MPH Associate Professor, Department of Medicine, Stanford University 
Jane Segebrecht, MPH Public Health Analyst, Team Lead, HHS HRSA 
Sayeedha Uddin, MD, MPH Senior Public Health Analyst, HHS OWH 
Cora Lee Wetherington, PhD Women & Sex/Gender Differences Research Coordinator, NIH NIDA 
Jessica White, MPP Social Science Analyst and CDC Team Lead, Division of Science Policy, HHS ASPE 
Scott Winiecki, MD Lead Medical Officer, FDA CDER PASE 

 


Back to Top